MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis

Neuroscience

Volumn 169, Issue 1, 2010, Pages 370-377

  Zhang, Z Y ^a   Zhang, Z ^a   Schluesener, H J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Experimental autoimmune neuritis; Foxp3+ T cell; HDAC inhibitor; M2 macrophage; MS 275

Indexed keywords

GAMMA INTERFERON; GELATINASE B; HISTONE DEACETYLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; MESSENGER RNA; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DEMYELINATING DISEASE; DEMYELINATION; DISEASE DURATION; DISEASE SEVERITY; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; NEURITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SCIATIC NERVE; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; CYTOKINES; DEMYELINATING DISEASES; DRUG EVALUATION, PRECLINICAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; INFLAMMATION; LYMPH NODES; LYMPHOCYTE SUBSETS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; NITRIC OXIDE SYNTHASE TYPE II; PYRIDINES; RATS; RATS, INBRED LEW; RNA, MESSENGER; SCIATIC NERVE;

EID: 77953810971     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.074     Document Type: Article

References (36)

1. Abramson S.B., Amin A.R., Clancy R.M., Attur M. The role of nitric oxide in tissue destruction. Best Pract Res Clin Rheumatol 2001, 15:831-845.
2. Adcock I.M. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 2006, 7:966-973.
3. Aranami T., Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008, 2008:115-120.
4. Badylak S.F., Valentin J.E., Ravindra A.K., McCabe G.P., Stewart-Akers A.M. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A 2008, 2008:1835-1842.
5. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H) 17 cells. Nature 2008, 453:1051-1057.
6. Blanchard F., Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 2005, 10:197-204.
7. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8:337-348.
8. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528.
9. Glauben R., Sonnenberg E., Zeitz M., Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009, 280:154-159.
10. Gold R., Hartung H.P., Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000, 6:88-91.
11. Gurvich N., Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002, 96:45-66.
12. Han S.B., Lee J.K. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 2009, 32:613-624.
13. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007, 39:1388-1405.
14. Hughes P.M., Wells G.M., Clements J.M., Gearing A.J., Redford E.J., Davies M., Smith K.J., Hughes R.A., Brown M.C., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998, 121:481-494.
15. Kieseier B.C., Kiefer R., Gold R., Hemmer B., Willison H.J., Hartung H.P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004, 30:131-156.
16. Kostrouchová M., Kostrouch Z., Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007, 53:37-49.
17. Li Y., Yuan Z., Liu B., Sailhamer E.A., Shults C., Velmahos G.C., Demoya M., Alam H.B. Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition. J Trauma 2008, 64:863-870.
18. Lin H.Y., Chen C.S., Lin S.P., Weng J.R., Chen C.S. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006, 26:397-413.
19. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., Bastianelli E., Baron R., Rawadi G., Clément-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872.
20. Lucas J.L., Mirshahpanah P., Haas-Stapleton E., Asadullah K., Zollner T.M., Numerof R.P. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009, 257:97-104.
21. Maurer M., Toyka K.V., Gold R. Cellular immunity in inflammatory autoimmune neuropathies. Rev Neurol 2002, 158:S7-S15.
22. Meyer zu Hörste G., Hartung H.P., Kieseier B.C. From bench to bedside-experimental rationalefor immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract 2007, 3:198-211.
23. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
24. Nencioni A., Beck J., Werth D., Grünebach F., Patrone F., Ballestrero A., Brossart P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007, 13:3933-3941.
25. O'Connor R.A., Anderton S.M. Multi-faceted control of autoaggression: Foxp3+ regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol 2008, 251:8-18.
26. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 10:3912-3922.
27. Sawalha A.H. Epigenetics and T-cell immunity. Autoimmunity 2008, 41:245-252.
28. Shahbazian M.D., Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007, 76:75-100.
29. Su R.C., Becker A.B., Kozyrskyj A.L., Hayglass K.T. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2008, 121:57-63.
30. Vandooren B., Noordenbos T., Ambarus C., Krausz S., Cantaert T., Yeremenko N., Boumans M., Lutter R., Tak P.P., Baeten D. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009, 60:966-975.
31. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 2008, 210:681-690.
32. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008, 65:4055-4065.
33. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats. Exp Neurol 2009, 216:75-82.
34. Zhang Z.Y., Zhang Z., Schluesener H.J. FTY720 attenuates lesional interleukin-17 cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2009, 35:487-495.
35. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
36. Zhu J., Mix E., Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998, 84:40-52.